Congenital Heart Disease (CHD) market

1
Congenital Heart Disease (CHD) Market Trends,
Size, Share, Demands, Overview, Growth, Revenue
and Forecast to 2030
sales_at_delvens.com www.delvens.com
2
Sternal Closure Systems Market Trends Forecast
Till 2030
Congenital Heart Disease (CHD) Market, by Type
(Heart Valve Defects, Heart Wall Defects, Blood
Vessel Defects, Others), Diagnosis
(Electrocardiogram, Chest X-ray, Echocardiogram,
Transoesophageal Echocardiogram, Pulse Oximetry,
Exercise Stress Test, Cardiac CT Scan or MRI,
Cardiac Catheterization, Other), Treatment
(Medications, Surgery, Watchful Waiting, Others),
Route of Administration (Oral, Parenteral,
Others), End Users (Hospitals, Specialty Clinics,
Others), Distribution Channel (Hospital Pharmacy,
Retail Pharmacy, Others), and region (North
America, Europe, Asia-Pacific, Middle East and
Africa and South America).
Request For Free Sample Report
https//www.delvens.com/get-free-sample/congenital
-heart-disease-chd-market
sales_at_delvens.com
www.delvens.com
3
Market Overview
Congenital Heart Disease (CHD) is a term used to
describe a range of structural defects in the
heart that are present at birth. These defects
can involve the walls, valves, arteries, or veins
of the heart, causing problems with blood flow
and affecting the hearts ability to pump blood
effectively. Some congenital heart defects are
mild and may not require treatment, while others
can be more severe and require medical
interventions such as surgery or medication. The
exact cause of most congenital heart defects is
not known, but a combination of genetic and
environmental factors is thought to play a
role. The growth of the global Congenital Heart
Disease (CHD) market is mainly driven by rising
prevalence of congenital heart disease globally.
Moreover, increased awareness, improved
diagnostic techniques, increased awareness and
better access to healthcare are expected to drive
the market further. In addition, the growing
emphasis on paediatric cardiology and specialized
care for children are expected to drive the
market further during the forecast
period. Purchase this Report
https//www.delvens.com/checkout/congenital-heart-
disease-chd-market
sales_at_delvens.com
www.delvens.com
4
Key Findings
The Congenital Heart Disease (CHD) Market is
segmented into Type, diagnosis, treatment, route
of administration, end users, distribution
channel, and region Based on type, the market
is segmented into heart valve defects, heart wall
defects, blood vessel defects, others. The heart
wall defects dominated the market in this
segment. This is due to the increase in the cases
of Ventricular septal defect (VSD) or hole in the
heart worldwide. Based on diagnosis, the market
is bifurcated into electrocardiogram, chest
x-ray, echocardiogram, transoesophageal
echocardiogram, pulse oximetry, exercise stress
test, cardiac CT scan or MRI, cardiac
catheterization, others. Electrocardiogram
dominated the market in this segment. This is
because Electrocardiogram is the most common
diagnostic tool to diagnose heart defects.
sales_at_delvens.com
www.delvens.com
5
Key Findings
Based on treatment, the market is segmented into
medications, surgery, watchful waiting, others.
Surgery dominated the market in this segment as
it is the most common treatment for CHD. Surgical
treatment can be performed open-heart surgery or
minimally invasive surgery. The market is also
divided into various regions such as North
America, Europe, Asia-Pacific, South America, and
Middle East and Africa. North America is
estimated to account for the largest market share
during the forecast period. Inquire Before
Buying https//www.delvens.com/Inquire-before-buy
ing/congenital-heart-disease-chd-market
sales_at_delvens.com
www.delvens.com
6
Competitive Landscape

• Abbott Laboratories
• AstraZeneca Plc
• Becton Dickson Co.
• Bio-Rad Laboratories
• Boston Scientific Corp.
• Laboratory Corporation of America Holdings
  (LabCorp)
• F. Hoffmann-La Roche Ltd.
• Glaxosmithkline Plc
• Janssen Pharmaceuticals, Inc.
• Medtronic
• Viatris Inc.

• Novartis Ag
• Pfizer, Inc.
• Randox Laboratories Ltd.
• Response Biomedical Corporation
• Sanofi S.A.
• Siemens Healthineers
• Thermo Fisher Scientific Inc.
• Vericel Corporation

sales_at_delvens.com
www.delvens.com
7
Recent Developments
In June 2023, Pfizer relaunched Eliquis, an
anticoagulant used to prevent the gradual
increase in the prevalence of stroke due to heart
condition called atrial fibrillation which is a
major concern being a common cause of death among
adults.  In July 2023, Novartis announced that
the US Food and Drug Administration (FDA)
approved a label update for Leqvio (inclisiran)
to enable earlier use in patients with elevated
LDL-C who have an increased risk of heart
disease, as an adjunct to diet and statin
therapy.
sales_at_delvens.com
www.delvens.com
8
Contact Information
About Us Delvens is a strategic advisory and
consulting company headquartered in New Delhi,
India. The company holds expertise in providing
syndicated research reports, customized research
reports and consulting services. Delvens
qualitative and quantitative data is highly
utilized by each level from niche to major
markets, serving more than 1K prominent companies
by assuring to provide the information on
country, regional and global business
environment. We have a database for more than 45
industries in more than 115 major countries
globally. Contact Us 44-20-3290-6466 1
214-377-1144 sales_at_delvens.com
sales_at_delvens.com
www.delvens.com